AlzeCure Pharma
11.10.2021 10:21:54 CEST | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / October 11, 2021 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company is participating at Redeye Neurology (CNS) Seminar on October 13 at 10:55 CEST, where CSO Johan Sandin will present the company's latest developments. The presentation will be followed by a panel discussion together with representatives from AlziNova and BioArctic and moderated by Redeye's analysts.
The presentation will be held in English and live streamed via https://www.redeye.se/events/815803/neurology-seminar-cns-3 . The presentation will also be available afterwards on AlzeCure's website https://www.alzecurepharma.se/en/presentations-and-interviews/ .
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se, is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se.
Image Attachments
Johan Sandin CSO AlzeCure Pharma
Attachments
AlzeCure presents at Redeye Neurology (CNS) Seminar on October 13
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/667525/AlzeCure-Presents-at-Redeye-Neurology-CNS-Seminar-on-October-13
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Polaris Renewable Energy Reminds Shareholders to Vote Ahead of Annual Meeting16.6.2026 00:30:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / June 15, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") today reminds shareholders to vote their common shares in advance of the Company's upcoming annual meeting of shareholders, which will be held virtually on June 18, 2026 at 9:00 a.m. Toronto time. Shareholders are encouraged to vote as soon as possible and prior to the proxy voting deadline of 9:00 a.m. Toronto time on June 16, 2026. Voting in advance helps ensure that shareholders' shares are represented at the meeting. At the meeting, shareholders will be asked to receive the consolidated financial statements of the Company for the year ended December 31, 2025, together with the report of the auditors thereon. Shareholders will also be asked to vote on the following matters: electing directors of the Company; and reappointing PricewaterhouseCoopers LLP, Chartered Accountants, as auditors of the Company and authorizing the directors of the Company to fix their remunerat
New Pharma AI Findings Reveal the Real Barrier to Scale: Execution, Not Innovation15.6.2026 12:00:00 CEST | Press release
GENEVA, SWITZERLAND AND WARSAW, POLAND / ACCESS Newswire / June 15, 2026 / Pharma companies are no longer struggling to identify AI opportunities - they are struggling to scale them. New findings from Lingaro, based on research with 150 senior pharma and life sciences leaders, show that AI has strong strategic visibility across the sector, yet most organizations lack the foundations needed to turn early momentum into consistent business impact. Nearly 60% of respondents say their AI strategy lacks clear ownership, highlighting a gap between leadership ambition and operational accountability. Without defined business ownership and success metrics, many companies remain stuck between experimentation and scaled delivery. Data is another barrier. According to the research, 67.3% of pharma leaders report fragmented or only partly reliable data. In a sector where commercial, medical, regulatory, and patient data often sit in disconnected systems, poor data quality can delay decisions, reduce
Litum Brings High-Precision Location Visibility to Zone 1 and Zone 2 Hazardous Environments15.6.2026 09:00:00 CEST | Press release
Combining ATEX Zone 1 and Zone 2 suitability with high-precision location capability, the ATEX Gateway and ATEX Dualis Tag set a new benchmark for intrinsically safe RTLS in hazardous industrial environments BOSTON, MA / ACCESS Newswire / June 15, 2026 / Litum, a global leader in real-time location systems, today announced the ATEX Family: a purpose-built hardware suite comprising the ATEX Gateway and ATEX Dualis Tag. Compliant with both Zone 1 and Zone 2 hazardous areas, the ATEX Family is designed to deliver sub-meter location accuracy and better visibility in environments where standard connected devices cannot be safely deployed. The launch marks a significant step forward for industrial organizations that need to track critical assets, equipment, tools, materials, and people in environments where explosive gases, vapors, or combustible dust may be present. By combining intrinsically safe design with Ultra-Wideband (UWB) and Bluetooth Low Energy (BLE) location capability, Litum ena
GA-ASI and INTEC Group Sign MOU at ILA Berlin11.6.2026 17:00:00 CEST | Press release
BERLIN, DE / ACCESS Newswire / June 11, 2026 / Today at the ILA Berlin Air Show, General Atomics Aeronautical Systems, Inc. (GA-ASI) and the INTEC Group signed a Memorandum of Understanding (MoU) for INTEC to support the architecture and integration of mission systems, entry into service and logistic support services for GA-ASI's Gambit Series of Collaborative Combat Aircraft (CCA). The work is intended to provide sovereign capabilities to meet the growing interest in CCA in Germany. The MoU was signed by GA-ASI CEO Linden Blue and INTEC Group CEO Christoph Otten. GA-ASI's flight-proven Gambit CCA provides a common platform for air-to-air, air-to-ground and electronic warfare missions. Gambit is an uncrewed combat jet optimized for attack roles such as electronic warfare, Suppression of Enemy Air Defenses (SEAD), Destruction of Enemy Air Defenses (DEAD) and stand-off precision strike, making it a versatile option for evolving security needs. GA-ASI is currently flight testing the YFQ-4
U.S. Polo Assn. Palm Beaches Marathon Celebrates America's 250th, Adds $17,000 in Prize Money as it Returns December 12-13, 202611.6.2026 13:00:00 CEST | Press release
WEST PALM BEACH, FL / ACCESS Newswire / June 11, 2026 / The 2026 U.S. Polo Assn. Palm Beaches Marathon, a celebration of America's 250th, will introduce prize money for its top Marathon runners for the first time when the race returns to the streets of West Palm Beach on December 12-13, 2026, a move that will attract elite runners worldwide and elevate the status of Palm Beach County's most treasured road test. The introduction of $17,000 in prize money is the next strategic step for elevating this racing event that has experienced record growth in recent years. The men's and women's winners of the Marathon race will each receive $5,000, second-place finishers will receive $2,500, and third place will be worth $1,000. The winners' share of the purse is the largest in the state of Florida. In celebration of America's 250th, the 2026 U.S. Polo Assn. Palm Beaches Marathon Logo has been re-designed in stunning brushstrokes of red, white and blue to accompany the brand's iconic double horse
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom